Pfizer sued over COVID-19 antiviral drug

Pfizer is facing a lawsuit centring on its COVID-19 antiviral, Paxlovid (nirmatrelvir tablets; ritonavir tablets), after Enanta Pharmaceuticals filed a complaint citing patent infringement.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Pharma company hit with racial discrimination lawsuit

20 September 2022 Pfizer’s ‘Breakthrough’ programme is aimed at Black, Latino and Native Americans | A healthcare membership organisation filed the complaint.

Americas

Pfizer bolsters haematology expertise with $5.4bn deal

9 August 2022 Pharma giant to acquire biopharma firm specialising in sickle cell treatment | Key treatment will be distributed to countries most impacted by the disease.

Big Pharma

Pfizer commits to offer drugs not-for-profit to 45 low-income countries

31 May 2022 Pfizer has announced that it will provide all of its current and future patent-protected medicines and vaccines—that are available in the US or EU—on a not-for-profit basis to 45 lower-income countries.

More features

The Quintara decision: Defining trade secrets in federal cases

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Pfizer sued over COVID-19 antiviral drug

More on this story

Editor's picks

Editor's picks

More features